IDEAYA Biosciences (IDYA) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Key program updates and clinical milestones

• Multiple first-in-class programs advancing, with six in the clinic and three INDs targeted for 2025.

• Darovasertib registrational trial in metastatic uveal melanoma expects median PFS readout by year-end 2025, with overall survival data and a second registration trial to start in H1 2025.

• Neoadjuvant uveal melanoma trial to provide >70 patient data and regulatory update in 2025; protocol finalization and study launch targeted for H1 2025.

• IDE397 (MAT2A inhibitor) in phase II for MTAP-deleted tumors, showing ~30% response rate and >90% disease control in early data.

• IDE849 (DLL3 ADC) acquired for small cell lung cancer, showing robust monotherapy activity and planned combinations with IDE161.

Strategic focus and business development

• Pipeline strategy centers on high-conviction, biomarker-enabled, rational combinations, often aiming for first-in-class status.

• Business development is used to accelerate internal strategy, especially for assets enabling key combinations, with openness to global opportunities.

• Recent acquisitions in the ADC space complement the synthetic lethality platform, with plans to combine technologies.

Clinical and preclinical pipeline highlights

• IDE161 (PARG inhibitor) in phase I, focusing on endometrial cancer and combinations with checkpoint inhibitors and ADCs.

• IDE275 (Werner helicase inhibitor) with GSK targets MSI-high tumors, showing strong preclinical activity and moving toward phase II.

• IDE705 (Pol Theta helicase inhibitor) addresses PARP resistance, with dramatic preclinical responses in combination with PARP inhibitors.

• IND-enabling studies ongoing for B7-H3 PTK7 bispecific ADC and dual KAT6 inhibitor IDE251, both showing promising preclinical efficacy.